Treatment Of Endometrial Hyperplasia

Comparison Of The Effect Of adding Metformin to progesterone in The Treatment Of Endometrial Hyperplasia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221015056181N1

Enrollment

134

Registered

2022-12-04

Start date

2022-12-22

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Hyperplasia. Endometrial hyperplasia

Interventions

Intervention 1: Intervention group: Metformin and megestrol receptor. Intervention 2: Control group: Megestrol and placebo recipients.

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Having a pathological diagnosis of EEC or AEH Desire to preserve fertility Not having suspicious signs of tissue invasion No hormonal treatment in the last 6 months Obtain informed consent Age 18 to 45 years

Exclusion criteria

Exclusion criteria: Contraindications for metformin Contraindications for progesterone (megestrol) Use of metformin in the last six months Blood sugar less than 60 or more than 200 mg/dL Using oral contraceptives or estrogen or progesterone Alcohol addiction Severe infection Severe chronic disease (impairment of heart, liver, lung or kidney function)

Design outcomes

Primary

Measure	Time frame
Endometrial Hyperplasia. Timepoint: Examination of endometrial hyperplasia after 3 weeks of treatment. Method of measurement: Endometrial biopsy.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactmonire mirzaei

Ghoum University of Medical Sciences

moniremirzaee??@gmail.com+98 25 3133 3333

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026